Navigation Links
Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
Date:10/10/2007

BOULDER, Colo. and MONTREAL, Oct. 10 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced the initiation of a Phase One clinical trial evaluating MGCD0103, the Companies' isotype-selective histone deacetylase inhibitor (HDACi) product candidate, in combination with Taxotere(R) (docetaxel; Sanofi Aventis) in patients with solid tumors. Taxotere is an approved chemotherapy agent marketed for use in breast, lung, prostate, gastric and head and neck cancer.

In the first portion of the trial, MGCD0103 will be given orally, three times per week for three weeks in combination with Taxotere, which will be administered on Day 1 of each three-week cycle to patients with cancer where treatment with Taxotere is approved or considered standard of care, or patients who have no available standard of care therapeutic options. Key objectives for this portion of the study will be threefold: to evaluate the safety of administering these two agents together; determine the maximum tolerated dose of MGCD0103 when combined with the two fixed doses of Taxotere; and to define optimal dosing for the second portion of the trial. In the second portion of the trial, objectives include further assessment of the safety of the drug combination, quantification of tumor responses and measurement of the pharmacodynamic and pharmacokinetic characteristics. The trial may enroll up to 50 patients at cancer centers in North America. The trial is expected to take 12 to 18 months to complete.

"This is an important step forward in the clinical development of MGCD0103," said Andrew Allen, executive vice president and chief medical officer of Pharmion Corporation. "Cytotoxic chemotherapies such
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... ANDOVER, Massachusetts y LONDRES, August 30, 2015 ... conectada ofrece una visión holística de l ... de todo el trayecto   ... anunciado hoy el debut europeo de IntelliSpace Cardiovascular ... información que ofrece sofisticadas herramientas para acceder, analizar y ...
(Date:8/28/2015)... 28, 2015  With the heroin epidemic in ... Jacksonville -based Lakeview Health drug and ... helping to explain why fentanyl is causing a new ... 50 times more potent than pharmaceutical grade heroin and ... the risk of death skyrockets. "Fentanyl can ...
(Date:8/28/2015)... 28, 2015  CytomX Therapeutics, Inc., a biopharmaceutical company ... announced the filing of a registration statement on Form ... relating to a proposed initial public offering of its ... and the price range for the offering have not ... stock under the symbol "CTMX" on the NASDAQ Global ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2CytomX Files Registration Statement for Proposed Initial Public Offering 2
... Discovery Laboratories, Inc. (Nasdaq: DSCO) ... in the Journal of Neonatal-Perinatal Medicine, nearly ... about the exposure of newborn children to animal-derived medications. ... intensive care unit (NICU) who were interviewed in the ...
... Oct. 18, 2011 Bend Research Inc. ( www.bendresearch.com ... has announced a full schedule of events at the ... of Pharmaceutical Scientists (AAPS) in Washington, D.C. ... the last few years and we are now working ...
Cached Medicine Technology:New Study Shows Neonatologists and Parents of NICU Infants Share Concern Regarding Newborn Exposure to Animal-Derived Medications 2New Study Shows Neonatologists and Parents of NICU Infants Share Concern Regarding Newborn Exposure to Animal-Derived Medications 3Bend Research Announces Schedule of Events at 2011 AAPS Annual Meeting and Exposition 2Bend Research Announces Schedule of Events at 2011 AAPS Annual Meeting and Exposition 3
(Date:8/31/2015)... ... 31, 2015 , ... All birth control methods work best if used correctly ... among birth control methods. Moreover, no-scalpel vasectomy has many proven advantages with a lower ... vasectomy done because they are afraid of complications. , One Stop Medical Center ...
(Date:8/31/2015)... ... August 31, 2015 , ... healthbeautydistributors.com has been in business ... marketing a doctor note service to be made available to all patients and ... each generated excuse, much less than the average daily pay of workers. ...
(Date:8/31/2015)... ... , ... The Marietta dentists and staff at Verde Pointe Dental ... and staff ran a 5K race, the Iron Horse for Enduring Hearts on August ... sponsored the event to help support projects with funding to increase understanding of clinical ...
(Date:8/30/2015)... ... August 31, 2015 , ... The acknowledgement from Caribbean Journal comes after Grace ... 2015. The island of Providenciales itself received a TripAdvisor Traveller's Choice Award in ... Bay is offering a special promotion for newlyweds and honeymooners to celebrate this amazing ...
(Date:8/30/2015)... Wilmington, DE (PRWEB) , ... August 31, 2015 ... ... an exhibitor at the AHCA/NCAL 66th Annual Convention & Expo October 5th & ... providers and organizations together, the AHCA/NCAL convention brings industry professionals from all over ...
Breaking Medicine News(10 mins):Health News:One Stop Medical Center of Twin Cities Achieves Zero Failure Rate and Infection Rate in No Scalpel Vasectomy 2Health News:Verde Pointe Dental Associates Runs a 5K for Enduring Hearts 2Health News:Grace Bay Beach Named a Top Beach Destination for Weddings 2Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2
... State ... Center Implants Two ... TUSTIN, Calif. and SYDNEY, April 22 Sunshine Heart ... announced today that The Ohio State University Medical Center in Columbus, ...
... Parks to hold second annual Walk-a-thon event THIS SUMMERNEW YORK, ... Six Flags, and Cure Kids Cancer have teamed up once ... its "A Walk In The Park" program. This unique ... properties April 26 through July 26 offering local neighborhoods a ...
... DC Raised Tobacco Taxes--WASHINGTON, April 22 According to a ... to be a slow year for tobacco control policies on ... steps that are needed to curb tobacco use and save ... Legislated Actions on Tobacco Issues or SLATI , ...
... NIJMEGEN, The Netherlands, April 22 InteRNA,Technologies ... have entered,into a research agreement to develop ... Under the research collaboration ... InteRNA,s unique lentiviral-based miRNA,overexpression library will be ...
... one serving a week, , , WEDNESDAY, April 22 (HealthDay News) ... acids appear to have a reduced risk of heart failure, ... U.S. and Swedish researchers followed nearly 40,000 Swedish men, ages ... their health outcomes. During that time, 597 men with no ...
... Advocacy Groups Join Together to Ask President Obama for a Greater ... ... TN (PRWEB) April 22, 2009 -- In recent days, both ... a greater voice in the healthcare reform debate. Understanding that ...
Cached Medicine News:Health News:Video: U.S. Announcement - First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure 2Health News:Video: U.S. Announcement - First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure 3Health News:Video: U.S. Announcement - First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure 4Health News:Six Flags Friends Invites Guests to Help Cure Kids Cancer by Taking 'A Walk In The Park' 2Health News:Six Flags Friends Invites Guests to Help Cure Kids Cancer by Taking 'A Walk In The Park' 3Health News:Six Flags Friends Invites Guests to Help Cure Kids Cancer by Taking 'A Walk In The Park' 4Health News:New American Lung Association Report Reveals States Failing to Enact Lifesaving Tobacco Control Policies 2Health News:New American Lung Association Report Reveals States Failing to Enact Lifesaving Tobacco Control Policies 3Health News:InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer 2Health News:Fatty Fish May Cut Heart Failure Risk in Men 2Health News:Millennials Push For Seat at the Table on Healthcare Reform 2
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
Medicine Products: